Core Insights - The Ritz-Carlton, Naples is hosting its inaugural "NYE Black-Tie Gala" on New Year's Eve, featuring a luxurious five-course dinner and live jazz performances by Stella Cole, marking a significant addition to the resort's event offerings [2][3]. Event Details - The gala includes a 'Meet the Artist' reception, a five-course dinner curated by Executive Chef Satish Yerramilli, and a live performance by Stella Cole, culminating in a midnight countdown [4][5]. - Guests can enjoy premium bar selections and receive an autographed album of Stella Cole's debut release [5]. Ticket Pricing - Ticket options include Premiere Seating at $650 per person, Reserved Seating at $525 per person, and Large Table Reservations starting from $500 per person, all packages inclusive of taxes, gratuity, and valet parking [7]. Room Reservations - An exclusive "NYE Black-Tie Gala" package is available, which includes an overnight stay in a Coastal View Guestroom and two reserved seating-level tickets for the gala [8]. About The Ritz-Carlton, Naples - The Ritz-Carlton, Naples is a luxury resort featuring 474 guest rooms, a newly renovated Vanderbilt Tower, and various dining venues, recognized for its high standards and numerous accolades [10].

DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 third quarter financial results and provide a business and financial update.  Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 9 ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at ...

Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with speci ...

Core Viewpoint - Jazz Pharmaceuticals' shares increased nearly 6% following positive results from the phase III IMforte study, which evaluated the combination of Zepzelca and Roche's Tecentriq in treating extensive-stage small cell lung cancer [1][2]. Group 1: Study Results - The IMforte study demonstrated statistically significant improvements in overall survival and progression-free survival for the Zepzelca-Tecentriq combination compared to Tecentriq alone [2]. - The combination therapy was well-tolerated among participants, with no new safety signals reported [2]. Group 2: Regulatory Plans - Jazz Pharmaceuticals plans to submit a regulatory filing in the first half of 2025 for the Zepzelca-Tecentriq combination as a first-line maintenance treatment for extensive-stage small cell lung cancer [3]. - PharmaMar, which licensed Zepzelca to Jazz, also intends to submit a regulatory filing with the EMA for the same combination in the first half of 2025 [4]. Group 3: Current Market Performance - Year-to-date, Jazz Pharmaceuticals' shares have decreased by 4.6%, while the industry has seen a decline of 2.9% [3]. - Jazz's Zepzelca has been under accelerated FDA approval since 2020 for treating adult patients with metastatic small-cell lung cancer previously treated with platinum-based chemotherapy [3]. Group 4: Future Studies - The company is currently conducting the confirmatory phase III LAGOON study to evaluate Zepzelca for patients with relapsed small cell lung cancer, with plans to convert accelerated approval to full approval if results are positive [3].

Group 1 - Investors have not fully recognized the significance of two recent legal victories for Jazz Pharmaceuticals, which are expected to enhance the company's long-term prospects [2] - The first legal win was a partial victory against a competitor, indicating a positive shift in the competitive landscape for Jazz Pharmaceuticals [2] Group 2 - The article emphasizes the importance of tracking attractive risk/reward situations in the biotech sector, suggesting that there are potential growth stocks worth considering [2]

Core Insights - Jazz Pharmaceuticals is expanding its market presence beyond narcolepsy into the non-small cell lung cancer (NSCLC) market with the new drug Zanidatamab, which has a market potential of $32 billion, potentially adding $1.6 billion in revenue if a 5% market share is captured [1][13] - The company generated $3.83 billion in revenue in 2023, with 70.4% from neuroscience drugs, primarily narcolepsy treatments [2][3] - The narcolepsy market is valued at $2.5 billion, with Jazz holding a 73.64% market share, but growth in this segment is slowing [2][3] - Jazz's epilepsy pipeline, including Epidiolex and Sativex, generated $845.06 million in 2023, capturing approximately 8.9% of the estimated $9.6 billion global epilepsy market [3][4] - The leukemia pipeline generated $541.69 million in 2023, representing a 15.7% market share of the $3.44 billion leukemia market [4][5] - Zepzelca, targeting small cell lung cancer, generated $289.53 million in 2023, capturing 8.41% of its $3.44 billion market [7][9] - Defitelio, for stem cell transplantation, generated $184 million in 2023 but has seen declining sales [10][11] Financial Projections - Projected revenue for Jazz Pharmaceuticals could reach approximately $4.012 billion in 2024, with a potential total of $6.097 billion in 2025 if Zanidatamab captures 5% of the NSCLC market [15][18] - The company has maintained a net profit margin of around 10% to 15%, achieving 10.82% in 2023 [16][17] - Based on projected profits, the earnings per share (EPS) could be $9.69, with a current price-to-earnings (P/E) ratio of 11.13, indicating potential undervaluation compared to peers [18][19] Market Position and Strategy - Jazz Pharmaceuticals has a strong foothold in the narcolepsy market but faces challenges in further growth due to market maturity [2][13] - The company is actively pursuing legal actions to defend its market position against competitors [3] - Jazz is diversifying its portfolio with new drugs in development, including Zanidatamab, Suvecaltamide, and JZP898, to mitigate reliance on existing markets [13][14] - The company has a history of adapting its product offerings based on market needs, as seen with the introduction of Xywav [14]

Core Insights - Jazz Pharmaceuticals focuses on neuroscience and oncology, with significant revenue derived from sleep disorder drugs Xywav and Xyrem, and a growing oncology portfolio [1][6] Group 1: Sleep Disorder Portfolio - Jazz's sleep disorder portfolio includes two commercialized drugs, Xyrem and Xywav, with ongoing development activities in the sleep therapeutic area [3] - Xywav, approved by the FDA in July 2020, is the first and only treatment for idiopathic hypersomnia, expanding its label in August 2021 [4] - The transition of patients from Xyrem to Xywav is negatively impacting Xyrem sales but positively contributing to Xywav's growth due to its low-sodium formulation [5] Group 2: Oncology Portfolio - Jazz markets four oncology drugs, contributing over 25% of product revenues in the first half of 2024, with expectations of generating $1.10 billion to $1.15 billion in product sales from oncology in 2024 [6][7] - The oncology portfolio includes both older drugs like Defitelio and Vyxeos, and newer drugs such as Rylaze and Zepzelca, with increasing contributions from the latter [6] - Key pipeline candidates include zanidatamab, currently under regulatory review for biliary tract cancer, with a final FDA decision expected by November 24 [7] Group 3: Neuroscience Portfolio - The acquisition of GW Pharmaceuticals in 2021 introduced cannabidiol drugs like Epidiolex and Sativex, diversifying Jazz's neuroscience portfolio and reducing reliance on the oxybate franchise [8] - Epidiolex is expected to achieve blockbuster status by 2025, driven by a growing global prescriber base and ongoing studies for new indications [8] Group 4: Stock Performance and Estimates - Jazz's stock has increased by 5.3% over the past three months, compared to a 10.3% increase in the industry [9] - Earnings estimates for 2024 have risen from $19.36 to $19.53 per share, and for 2025 from $21.70 to $21.88 per share over the past 60 days [11] - Despite recent pipeline setbacks, Jazz's improving earnings performance and ongoing innovation support a positive outlook for the stock [12]

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation met ...

Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of 15.2 months and a Kaplan-Meier–estimated overall survival (OS) of 59% at 30 months DUBLIN, Sept. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of ...